Emerging Biologics and PCSK9 Inhibitors in the Atherosclerosis Drug...

added blog Haber

2026-05-21 13:06:52

Emerging Biologics and PCSK9 Inhibitors in the Atherosclerosis Drug Market

Atherosclerosis remains one of the leading causes of heart attacks, strokes, and peripheral artery diseases worldwide. The growing aging population, unhealthy lifestyles, obesity, diabetes, and hypertension are contributing significantly to the rising patient pool. Pharmaceutical companies are focusing on innovative therapeutic approaches, including anti-platelet medications, ACE inhibitors,...

0 Comments 0 Shares 10 Views 0 Reviews